Yongjie Ma1, Mingming Gao1, Dexi Liu2. 1. Department of Pharmaceutical and Biomedical Sciences, University of Georgia College of Pharmacy, Athens, Georgia, USA. 2. Department of Pharmaceutical and Biomedical Sciences, University of Georgia College of Pharmacy, Athens, Georgia, USA. dliu@uga.edu.
Abstract
PURPOSE: To study the effects of N-acetylcysteine (NAC, C5H9NO3S) on diet-induced obesity and obesity-related metabolic disorders. METHODS: Six-week-old male C57BL/6 mice fed a chow or high-fat diet (HFD) were treated with NAC (2 g/L) in drinking water for 11 weeks. Its influences on body weight and food intake were manually measured, and influence on body composition were analyzed by magnetic residence imaging. Glucose meter and ELISA were used to determine serum glucose and insulin levels, as well as lipid content in the liver. The effects of NAC treatment on mRNA levels of genes involved in inflammation, thermogenesis, and lipid metabolism in various tissues were determined by real time PCR. RESULTS: NAC supplementation inhibited the increase of fat mass and the development of obesity when mice were fed an HFD. NAC treatment significantly lowered HFD-induced macrophage infiltration, and enhanced adiponectin gene expression, resulting in reduced hyperglycemia and hyperinsulinemia, and improvement of insulin resistance. NAC oral administration suppressed hepatic lipid accumulation, as evidenced by lower levels of triglyceride and cholesterol in the liver. The beneficial effects are associated with a decrease of hepatic Pparγ and its target gene expression, and an increase in the expression of genes responsible for lipid oxidation and activation of farnesoid X receptor. Furthermore, NAC treatment also stimulates expression of thermogenic genes. CONCLUSION: These results provide direct proof of the protective potential of NAC against HFD-induced obesity and obesity-associated metabolic disorders.
PURPOSE: To study the effects of N-acetylcysteine (NAC, C5H9NO3S) on diet-induced obesity and obesity-related metabolic disorders. METHODS: Six-week-old male C57BL/6 mice fed a chow or high-fat diet (HFD) were treated with NAC (2 g/L) in drinking water for 11 weeks. Its influences on body weight and food intake were manually measured, and influence on body composition were analyzed by magnetic residence imaging. Glucose meter and ELISA were used to determine serum glucose and insulin levels, as well as lipid content in the liver. The effects of NAC treatment on mRNA levels of genes involved in inflammation, thermogenesis, and lipid metabolism in various tissues were determined by real time PCR. RESULTS:NAC supplementation inhibited the increase of fat mass and the development of obesity when mice were fed an HFD. NAC treatment significantly lowered HFD-induced macrophage infiltration, and enhanced adiponectin gene expression, resulting in reduced hyperglycemia and hyperinsulinemia, and improvement of insulin resistance. NAC oral administration suppressed hepatic lipid accumulation, as evidenced by lower levels of triglyceride and cholesterol in the liver. The beneficial effects are associated with a decrease of hepatic Pparγ and its target gene expression, and an increase in the expression of genes responsible for lipid oxidation and activation of farnesoid X receptor. Furthermore, NAC treatment also stimulates expression of thermogenic genes. CONCLUSION: These results provide direct proof of the protective potential of NAC against HFD-induced obesity and obesity-associated metabolic disorders.
Authors: Alexander Bartelt; Oliver T Bruns; Rudolph Reimer; Heinz Hohenberg; Harald Ittrich; Kersten Peldschus; Michael G Kaul; Ulrich I Tromsdorf; Horst Weller; Christian Waurisch; Alexander Eychmüller; Philip L S M Gordts; Franz Rinninger; Karoline Bruegelmann; Barbara Freund; Peter Nielsen; Martin Merkel; Joerg Heeren Journal: Nat Med Date: 2011-01-23 Impact factor: 53.440
Authors: Rabindra Tirouvanziam; Carol K Conrad; Teodoro Bottiglieri; Leonore A Herzenberg; Richard B Moss; Leonard A Herzenberg Journal: Proc Natl Acad Sci U S A Date: 2006-03-13 Impact factor: 11.205
Authors: Maureen J Charron; Lyda Williams; Yoshinori Seki; Xiu Quan Du; Bhagirath Chaurasia; Alan Saghatelian; Scott A Summers; Ellen B Katz; Patricia M Vuguin; Sandra E Reznik Journal: Diabetes Date: 2020-05-22 Impact factor: 9.461
Authors: Logan K Townsend; Alyssa J Weber; Pierre-Andre Barbeau; Graham P Holloway; David C Wright Journal: Am J Physiol Cell Physiol Date: 2019-11-13 Impact factor: 4.249
Authors: Steven Tun; Caleb James Spainhower; Cameron Lee Cottrill; Hari Vishal Lakhani; Sneha S Pillai; Anum Dilip; Hibba Chaudhry; Joseph I Shapiro; Komal Sodhi Journal: Front Pharmacol Date: 2020-08-13 Impact factor: 5.810
Authors: Paz García-Campos; Ximena Báez-Matus; Carlos Jara-Gutiérrez; Marilyn Paz-Araos; César Astorga; Luis A Cea; Viviana Rodríguez; Jorge A Bevilacqua; Pablo Caviedes; Ana M Cárdenas Journal: Int J Mol Sci Date: 2020-06-16 Impact factor: 5.923
Authors: Marco Raffaele; Ignazio Barbagallo; Maria Licari; Giuseppe Carota; Giuseppe Sferrazzo; Mariarita Spampinato; Valeria Sorrenti; Luca Vanella Journal: Evid Based Complement Alternat Med Date: 2018-10-17 Impact factor: 2.629
Authors: Lianggong Ding; Wenfei Sun; Miroslav Balaz; Anyuan He; Manuel Klug; Stefan Wieland; Robert Caiazzo; Violeta Raverdy; Francois Pattou; Philippe Lefebvre; Irfan J Lodhi; Bart Staels; Markus Heim; Christian Wolfrum Journal: Nat Metab Date: 2021-12-13
Authors: Schérolin de Oliveira Marques; Alexandre Pastoris Muller; Thais Fernandes Luciano; Natália Dos Santos Tramontin; Mateus da Silva Caetano; Bruno Luis da Silva Pieri; Tatiane Lima Amorim; Marcone Augusto Leal de Oliveira; Cláudio Teodoro de Souza Journal: Nutrients Date: 2022-07-15 Impact factor: 6.706